OraSure Technologies Inc.

Based in the US, OraSure Technologies Inc. operates in the biomedical sector, focusing on innovative diagnostic tests and sample collection solutions to improve healthcare access and efficacy worldwide. OraSure Technologies Inc. was founded in 1987 in Bethlehem, US, specializing in rapid diagnostic testing and sample collection solutions.

The company is led by CEO Stephen Tang, who has a history of contributing to advancements in healthcare technologies. OraSure Technologies, Inc. primarily specializes in the development, manufacture, and distribution of rapid diagnostic tests and sample collection solutions designed to enhance healthcare accessibility and efficacy. Their core product offerings include innovative testing devices and stabilization technologies targeted towards detecting critical medical conditions such as HIV, syphilis, and hepatitis C (HCV).

These products are designed for use in various healthcare settings including clinical laboratories, hospitals, physician’s offices, and community health organizations, thus serving a diverse clientele that encompasses public health entities, research institutions, and direct consumers globally. OraSure’s subsidiary companies, DNA Genotek and Sherlock Biosciences, complement its portfolio by focusing on advanced sample collection solutions, further extending their reach in both urban and rural markets across North America, Europe, and additional international regions. By providing effortless testing mechanisms, OraSure aims to bridge gaps in healthcare delivery, particularly in underserved communities. OraSure Technologies, Inc.

generates revenue primarily through the sale of its diagnostic testing products and sample collection solutions to a wide range of customers. Transactions typically occur through direct sales to healthcare providers, partnerships with public health organizations, and distribution to clinical laboratories and pharmaceutical companies. The company engages in B2B transactions, supplying its products to institutional clients while also facilitating direct-to-consumer sales for certain offerings. The revenue structure is indicative of a transactional model that includes bulk sales to healthcare facilities and individual purchases by consumers for at-home testing solutions.

OraSure’s flagship products, which include rapid diagnostic tests, contribute significantly to its revenue stream by addressing critical health concerns and improving testing access for populations in need.